Targets such as claudin-5, sphingosine-1 phosphate, or a disintegrin and metalloproteinase 15 (ADAM 15) may be interesting, as well as the use of liposomal nanocarriers to restore a degraded glycocalyx.39,44,45,78 Based on our findings, the next logical step will be to assess the therapeutic efficacy of restoring the glycocalyx and microcirculatory dysfunction in epilepsy models, which might ultimately be deployed clinically. The gene discussed is CLDN5; the disease is epilepsy.